rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Kimberly A. Reed

Director

Company insider

Files Form 4 as: Director, Takeda Pharmaceutical Company; Director, HA Sustainable Infrastructure Capital; Director, Momentus.

In numbers

Trades disclosed
33
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
3
Companies where not an officer
3
First trade
18 Oct 2021
Last trade
1 Jul 2026
Last filed
6 Jul 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
TAK Takeda Pharmaceutical CompanyDirector · Pharmaceuticals · last 6 Jul 20260 buys · 0 sells
HASI HA Sustainable Infrastructure CapitalDirector · Funds, Shells & SPACs · last 3 Jun 20260 buys · 0 sells
MNTS MomentusDirector · Aerospace & Defense · last 18 May 20260 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
—filed 6 Jul 2026TAK Takeda Pharmaceutical Companyoption or derivative · PharmaceuticalsSEC FORM 4 Code D$5.7M1,152 at $4,931.20filing
—filed 6 Jul 2026TAK Takeda Pharmaceutical Companyoption or derivative · PharmaceuticalsSEC FORM 4 Code D$5.7M1,152 at $4,931.20filing
1 Jul 2026filed 6 Jul 2026TAK Takeda Pharmaceutical CompanyPharmaceuticalsSEC FORM 4 Code A—3,800 at $0.00filing
1 Jul 2026filed 6 Jul 2026TAK Takeda Pharmaceutical Companyoption or derivative · PharmaceuticalsSEC FORM 4 Code A—1,319 at $0.00filing
1 Jul 2026filed 6 Jul 2026TAK Takeda Pharmaceutical Companyoption or derivative · PharmaceuticalsSEC FORM 4 Code A—1,319 at $0.00filing
1 Jul 2026filed 6 Jul 2026TAK Takeda Pharmaceutical CompanyPharmaceuticalsSEC FORM 4 Code A—3,800 at $0.00filing
3 Jun 2026filed 5 Jun 2026HASI HA Sustainable Infrastructure Capitaloption or derivative · Funds, Shells & SPACsSEC FORM 4 Code A—3,553 at $0.00filing
3 Jun 2026filed 5 Jun 2026HASI HA Sustainable Infrastructure Capitaloption or derivative · Funds, Shells & SPACsSEC FORM 4 Code A—3,553 at $0.00filing
18 May 2026filed 20 May 2026MNTS MomentusAerospace & DefenseSEC FORM 4 Code M—913 at $0.00filing
18 May 2026filed 20 May 2026MNTS Momentusoption or derivative · Aerospace & DefenseSEC FORM 4 Code A—6,039 at $0.00filing
18 May 2026filed 20 May 2026MNTS Momentusoption or derivative · Aerospace & DefenseSEC FORM 4 Code A—6,039 at $0.00filing
18 May 2026filed 20 May 2026MNTS MomentusAerospace & DefenseSEC FORM 4 Code M—913 at $0.00filing
30 Jun 2025filed 3 Jul 2025MNTS Momentusoption or derivative · Aerospace & DefenseSEC FORM 4 Code A—16,294 at $0.00filing
30 Jun 2025filed 3 Jul 2025MNTS MomentusAerospace & DefenseSEC FORM 4 Code A—16,294 at $0.00filing
4 Jun 2025filed 6 Jun 2025HASI HA Sustainable Infrastructure Capitaloption or derivative · Funds, Shells & SPACsSEC FORM 4 Code A—5,166 at $0.00filing
1 Nov 2024filed 5 Nov 2024MNTS Momentusoption or derivative · Aerospace & DefenseSEC FORM 4 Code M—222 at $0.00filing
1 Nov 2024filed 5 Nov 2024MNTS Momentusoption or derivative · Aerospace & DefenseSEC FORM 4 Code M—2,400 at $0.00filing
1 Nov 2024filed 5 Nov 2024MNTS MomentusAerospace & DefenseSEC FORM 4 Code M—222 at $0.00filing
1 Nov 2024filed 5 Nov 2024MNTS MomentusAerospace & DefenseSEC FORM 4 Code M—2,400 at $0.00filing
6 Jun 2024filed 7 Jun 2024HASI HA Sustainable Infrastructure Capitaloption or derivative · Funds, Shells & SPACsSEC FORM 4 Code A—6,126 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Lauren Rusckowski DupreyChief Transformation Officer · Chief Transformation Officer at Takeda Pharmaceutical Co, filing Form 4 there in the last year
Andrew Stewart PlumpPresident, R&D · President, R&D at Takeda Pharmaceutical Co, filing Form 4 there in the last year
Nicola Deidre Petal GreenwayChief Human Resources Officer · Chief Human Resources Officer at Takeda Pharmaceutical Co, filing Form 4 there in the last year
Ramy Riad Ahmed IbrahimPresident, PDT BU · President, PDT BU at Takeda Pharmaceutical Co, filing Form 4 there in the last year
Awny Samaan Botros FarajallahChief Medical Officer · Chief Medical Officer at Takeda Pharmaceutical Co, filing Form 4 there in the last year